Drug Utilization Review Board
Meeting Minutes, Open Session
January 18, 2023 10:00am – 2:00pm

Drug Utilization Review Board Due to COVID-19, this meeting was held virtually.	**Board Members:** Moneeshindra Mittal, MD, Chair James Backes, PharmD, Interim Chair *(Absent)* Gregory Burger, PharmD, CPPS, FASHP, EMT Daryl Callahan, D.O, MSS Jennifer Clair, MD Kristen Powell, PharmD Michele Reisinger, DNP, APRN, FNP-BC Arthur Snow, MD Cori Durall, PharmD **KDHE-DHCF/Contractor Staff:** Annette Grant, RPh Victor Nguyen, PharmD Sridevi Donepudi, MD Crystal Blackmon, Sr. Administrative Specialist *(Absent)* **MCO Staff:** Mark DeMary, RPh, Aetna Better Health of Kansas Angie Yoo, PharmD, Sunflower State Health Plan Sunny Bounyalath, PharmD, UnitedHealthcare Community Plan **Gainwell Technology Staff:** Karen Kluczykowski, RPh Kathy Kaesewurm, RN, BSN Harry Vu, PharmD Debra Illions-Clark, LPN	**Public attendees:** Amanda Nowakowski, Bradley, Cheryl Donahue, Donna Lee, Donna Osterlund, Ed Paiewonsky, Eric Hyde, Erin Hohman, Folger Tuggle, Gary Parenteau, Gina Heinen, Heather, Jeff Osmundson, Jenny Carrell, Jessica Chardoulias, Jordan Feuerborn, Jordon Wild, Karen Powell, Keith Gulley, Kevin Gallagher, Madison Elliott, Melissa Basil, Mike Dvorak, Rachel Boyer, Rusty Hailey, Sarah Sanders, Serena Barden, Susan [Non-identified participants are not listed.]

TOPIC	DISCUSSION	DECISION
I. Call to Order A. Introductions B. Announcements	**Call to Order:** Dr. Mittal called the meeting to order at 10:05am and proceeded to take roll call for the board members. **Introductions:** None. **Announcements:** Crystal Blackmon, Senior Administrative Specialist, who is taking over for Carole Arace, will be transitioning ownership of the meeting invites.	

TOPIC	DISCUSSION	DECISION
II. Old Business A. Review and Approval of the October 19, 2022 Meeting Minutes	**Board Discussion:** Dr. Mittal asked if there were any amendments/changes to the minutes requested.	Dr. Snow moved to approve the minutes. Dr. Burger second the motion. Motion to approve was carried unanimously.
III. New Business A. Executive Sign-off Agenda Items	**Background:** The 2 agenda items include: Adult Rheumatoid Arthritis Agents and Atopic Dermatitis Agents. **Board Discussion:** None	Dr. Powell moved to approve. Dr. Clair second the motion. Motion to approve was carried unanimously.
B. Revised Prior Authorization (PA) Criteria 1. Diabetes Mellitus- Type 2 Agents	**Background:** This revision includes the addition of Mounjaro®, removal of discontinued products, labeling updates for several agents and an update to a blanket statement regarding cosmetic use and other non-covered indications. **Public comment:** Jessica Chardoulias (Novo Nordisk) yielded her time back to the Board with the offer to answer any questions. **Board Discussion:** None	Dr. Snow moved to approve. Dr. Powell second the motion. Motion to approve was carried unanimously.
2. Hypercholesterolemia Agents	**Background:** This revision includes the addition of Leqvio® to the list of agents requiring prior authorization, changes to initial authorization criteria and an update to a blanket statement regarding cosmetic use and other noncovered indications. **Public comment:** Jordon Wild (Amgen) spoke on behalf of Repatha® and recommended that the criteria be changed to require an adequate trial of only one high intensity statin before instead of requiring an adequate trial of two high intensity statins. Sarah Sanders (Novartis) spoke on behalf of Leqvio® and recommended that the criteria be changed to require an adequate trial of only one PCSK9 instead of requiring an adequate trial of two PCSK9s. **Board Discussion:**	Dr. Burger moved to approve as amended. Dr. Snow second the motion. Motion to approve as amended was carried unanimously.

TOPIC	DISCUSSION	DECISION
	The State acknowledged the comment regarding the requirement of trial of at least 2 statins and noted that statins are considered first line. It was pointed out that failure or intolerance to one statin does not imply the same about another statin. The Board agreed that it is common for providers to trial two high intensity statins. Further discussion led to the revision from a 90-day trial, to 30-day trial of each statin. Review of PCSK9 trial was not discussed as it was not a part of the PA criteria. It was acknowledged that the question from Ms. Sanders was related to the PDL, which is not under the purview of the Board.	
3. Minimum Requirements Prior Authorization (MRPA)	**Background:** This revision includes the addition of Tegsedi®, Onpattro®, Ultomiris® and Amvuttra™ to the list of agents requiring prior authorization. Removal of Banzel and updates a blanket statement regarding cosmetic use and other non-covered indications. **Public comment:** Edward Paiewonsky (Alnylam) spoke on behalf of Onpattro® and Amvuttra™ and yielded his time back to the Board with the offer to answer any questions about Onpattro® and Amvuttra™. **Board Discussion:** None	Dr. Powell moved to approve. Dr. Snow second the motion. Motion to approve was carried unanimously.
4. Oncology - Auxiliary Treatment Agents	**Background:** This revision includes the addition of Rolvedon™, Pedmark®, Fylnetra® and Stimufend® to the list of agents requiring prior authorization and updates a blanket statement regarding cosmetic use and other non-covered indications. **Public comment:** Donna Lee (Fennec) spoke on behalf of Pedmark® and yielded her time back to the Board with the offer to answer any questions on Pedmark®. **Board Discussion:** None	Dr. Burger moved to approve. Dr. Snow second the motion. Motion to approve was carried unanimously.
C. <u>New Prior Authorization (PA) Criteria</u> 1. Hemophilia B Gene Therapy	**Background:** Hemgenix® (etranacogene dezaparvovec-drlb) is an adeno-associated virus vector-based gene therapy recently approved for the treatment of Hemophilia B. The prior authorization criteria are being proposed to ensure appropriate use based upon the FDA-approved labeling information and clinical guidelines.	Dr. Powell moved to approve. Dr. Snow second the motion. Motion to approve was carried unanimously.

TOPIC	DISCUSSION	DECISION
	Public comment: None. **Board Discussion:** The State noted that the title of the PA criteria had been changed to "Hemophilia B Gene Therapy". The Board asked about what is being done with the data that is being collected. The State clarified that the data might be used in retrospective review under circumstances where the drug was failing to improve the patient's condition. The State also alluded to potential contracting with manufacturers (i.e. value-based agreements) and acknowledged that other states have either implemented or are looking into implementing similar measures.	
D. Tentative Agenda Items 1. MHMAC Meeting (January 17, 2023) A. Antidepressant Medications – Safe Use for All Ages	**Background:** Possible revision of renewal criteria and other updates **Public comment:** None. **Board Discussion:** None.	Dr. Clair moved to approve. Dr. Powell second the motion. Motion to approve was carried unanimously.
B. Antipsychotic Medications – Safe Use for All Ages	**Background:** Possible revision of prior authorization criteria and other updates **Public comment:** Erin Hohman (Abbvie) was absent. Melissa Basil noted that she was unable to attend and yielded her time back to the Board. Kenneth Berry (Alkermes) was also absent. Time was yielded back to the Board. **Board Discussion:** The Board acknowledged and praised proposed changes.	Dr. Powell moved to approve. Dr. Callahan second the motion. Motion to approve was carried unanimously.
C. ADHD Medications – Safe Use for All Ages	**Background:** Possible revision of renewal criteria and other updates **Public comment:** None. **Board Discussion:** None.	Dr. Powell moved to approve. Dr. Callahan second the motion. Motion to approve was carried unanimously.

TOPIC	DISCUSSION	DECISION
D. Benzodiazepine Medications – Safe Use for All Ages	**Background:** Revision/clarification of dosing table **Public comment:** None **Board Discussion:** None.	Dr. Snow moved to approve. Dr. Burger second the motion. Motion to approve was carried unanimously.
2. PDL Meeting (January 17, 2023) – New PDL Classes B. Intravenous Iron Products: Feraheme®, Injectafer®, Monoferric®, Triferic® and Triferic Avnu®	**Background:** Addition of a new PDL class for intravenous iron products. **Public comment:** None. **Board Discussion:** None.	Dr. Snow moved to approve. Dr. Powell second the motion. Motion to approve was carried unanimously.
IV. Adjourn	The meeting adjourned at 11:54am.	Dr. Powell motioned to adjourn. Dr. Callahan seconded the motion. Motion to adjourn was carried unanimously.

The next DUR Board meeting is scheduled for April 19, 2023.

*Public comment is limited to five minutes per product; additional time will be allowed at the DUR Board's discretion.
Informal comments will be accepted from members of the audience at various points in the agenda.
All approved PA criteria are posted to the KDHE website: https://www.kdhe.ks.gov/206/General-Clinical-Prior-Authorization